Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Numerous clinical trials have reported renoprotective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, slowing progression to end-stage kidney disease in patients with diabetic kidney disease (DKD). Additionally, some studies have reported renoprotective effects in patients with non-diabetic kidney disease (non-DKD). To date, studies evaluating the effects of SGLT2 inhibitors in both DKD and non-DKD patients in clinical practice remain insufficient. In this study, we investigated the effects of SGLT2 inhibitors on eGFR trajectory in CKD patients with and without DKD.
We performed a retrospective, single-center, observational study. Patients newly prescribed SGLT2 inhibitors at Oita University Hospital between September 1, 2021, and May 31, 2024, were included in this study. The patients were divided into groups based on the presence and absence of DKD, early-stage chronic kidney disease (CKD) (eGFR ≥ 60 mL/min/1.73 m²), poor diabetes control (HbA1c ≥ 7.0%), and obesity (BMI ≥ 25). The eGFR slope before (12 months) and after initiation (the following 12 months) of SGLT2 inhibitor therapy was calculated in each group, and treatment response was defined as an improvement in eGFR slope ≥ 1.0 mL/min/1.73 m²/year.
A total of 131 patients were included in the study. Of these, 96 (73.3%) received dapagliflozin and 35 (26.7%) received empagliflozin.Overall, 52 patients (39.7%) were female, and the mean age was 57.4 ± 16.5 years, 66 (50.4%) had DKD, 60 (45.8%) had early-stage CKD, 48 (36.6%) exhibited poor diabetes control, 82 (62.6%) were obese, and 67 (51.1%) were prescribed RAS inhibitors. Among all patients, eGFR slope improved by +3.5 mL/min/1.73 m²/year and the mean urinary protein excretion decreased from 1.5 g/gCr before initiation to 1.2 g/gCr at 12 months, but the change was not statistically significant. In subgroup analyses, the changes in eGFR slope were +3.9 in the DKD group versus +3.0 in the non-DKD group, +4.9 in the eGFR ≥ 60 group versus +1.2 in the eGFR < 60 group, +4.8 in the poor glycemic control group versus +1.3 in the well-controlled diabetes group, and +4.2 in the obesity group versus +2.3 in the non-obesity group.
The 12-months treatment of SGLT2 inhibitors marginally reduced urinary protein excretion, but significantly improved chronic eGFR slope compared to that before SGLT2 inhibitor was started in CKD patients, regardless of presence of DKD. Our real world data suggest that renal benefit by SGLT2 inhibitors may be associated with multiple effects other than reducing intraglomerular hyperfiltration. These effects were more pronounced in patients with early stage CKD, poor diabetes control, and obesity.
